any news

hi anyone know anything about this

Orphan Drug Designation in European Union for GLP1690 For Idiopathic Pulmonary Fibrosis

today (6 sept 2016) at 16:30 CET hours

Galapagos is presenting

Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF

at the European respiratory Society Congress in London .

GLPG1690 is currently being evaluated in the FLORA study Phase two clinical trial . top line data by mid 2017

clinical trial NCT02738801

2 Replies

oldestnewest
  • Hi. I have not heard about this but very interested. My hubby has IPF. Best wishes x

  • Hi anode11,

    You can find out some more information about this trial at the UK Clinical Trials Gateway at ukctg.nihr.ac.uk/trials/tri...

    If you’re interested in other clinical trials in the UK for IPF or any other lung condition then you can visit the UK Clinical Trials Gateway ukctg.nihr.ac.uk Here you can search for clinical trials around the country by the name of the condition and it’ll also explain what happens on clinical trial and the reason for joining one. All clinical trials involving patients in the UK need to be registered and should appear on this website.

    You can also find out more about IPF research in general on our website at blf.org.uk/idiopathic-pulmo...

    If you’re interested in the research that the BLF fund then we have more information at blf.org.uk/research A lot of our research is funded through donations from our supporters, if you’d like to donate to life changing research for IPF or any other lung disease then you can visit blf.org.uk/donate

    Hope this helps!

    Thanks,

    Ben

You may also like...